Literature DB >> 10523001

Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.

J D Wallace1, R C Cuneo, R Baxter, H Orskov, N Keay, C Pentecost, R Dall, T Rosén, J O Jørgensen, A Cittadini, S Longobardi, L Sacca, J S Christiansen, B A Bengtsson, P H Sönksen.   

Abstract

GH abuse by elite athletes is currently undetectable. To define suitable markers of GH doping, we assessed the effects of acute exercise, GH administration, and GH withdrawal on the GH/insulin-like growth factor (IGF) axis in athletic adult males. Acute endurance-type exercise increased serum GH, GH-binding protein (GHBP), total IGF-I, IGF-binding protein (IGFBP)-3, and acid-labile subunit (ALS), each peaking at the end of exercise. IGFBP-1 increased after exercise was completed. Free IGF-I did not change with exercise. Recombinant human GH treatment (0.15 IU/kg x day) for 1 week increased serum total IGF-I, IGFBP-3, and ALS, exaggerating the responses to exercise. IGFBP-2 and IGFBP-1 were trivially suppressed. After GH withdrawal, the GH response to identical exercise was suppressed. Total IGF-I, IGFBP-3, and ALS returned to baseline over 3-4 days. In summary, 1) acute exercise transiently increased all components of the IGF-I ternary complex, possibly due to mobilization of preformed intact complexes; 2) GH pretreatment augmented the exercise-induced changes in ternary complexes; 3) postexercise IGFBP-1 increments may protect against delayed onset hypoglycemia; 4) serum total IGF-I, IGFBP-3, and ALS may be suitable markers of GH abuse; and 5) differences in disappearance times altered the sensitivity of each marker for detecting GH abuse.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523001     DOI: 10.1210/jcem.84.10.6037

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  GH responses to a near-maximal exercise training session on-the-field in cyclists.

Authors:  C L Lafortuna; P G Marinone; S Ottolini; A Sartorio
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

2.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

Review 4.  [Hormone therapy and anti-aging: is there an indication?].

Authors:  D Heutling; H Lehnert
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 5.  Hepatokines-a novel group of exercise factors.

Authors:  Cora Weigert; Miriam Hoene; Peter Plomgaard
Journal:  Pflugers Arch       Date:  2018-10-18       Impact factor: 3.657

6.  Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy.

Authors:  E Carro; J L Trejo; S Busiguina; I Torres-Aleman
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 7.  Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?

Authors:  M J Rennie
Journal:  Br J Sports Med       Date:  2003-04       Impact factor: 13.800

Review 8.  Growth factors as mediators of exercise actions on the brain.

Authors:  M Llorens-Martín; I Torres-Alemán; José L Trejo
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

9.  Acute hormonal responses of a high impact physical exercise session in early postmenopausal women.

Authors:  W Kemmler; L Wildt; K Engelke; R Pintag; M Pavel; B Bracher; J Weineck; W Kalender
Journal:  Eur J Appl Physiol       Date:  2003-07-09       Impact factor: 3.078

Review 10.  Brain repair and neuroprotection by serum insulin-like growth factor I.

Authors:  Eva Carro; Jose Luis Trejo; Angel Núñez; Ignacio Torres-Aleman
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.